Literature DB >> 24698736

Untreated highly viraemic pregnant women from Asia or sub-Saharan Africa often transmit hepatitis B virus despite serovaccination to newborns.

Pierre Sellier1, Sarah Maylin, Rishma Amarsy, Marie-Christine Mazeron, Lucile Larrouy, Stéphanie Haïm-Boukobza, Amanda Lopes, Maria-Dolores Moreno, Aude Ricbourg, Guy Simoneau, Jean-Dominique Magnier, Sophie Mercier-Delarue, Véronique Delcey, John Evans, Emmanuelle Cambau, Emmanuel Barranger, François Simon, Jean-François Bergmann.   

Abstract

BACKGROUND & AIMS: Mother-to-child (MTC) hepatitis B virus (HBV) transmission has been mainly studied in Asia. The geographical origins of women and HBV genotypes differ in Europe. The aims were to determine the rate and risk factors of MTC HBV transmission from women with high HBV DNA loads in a maternity hospital in Paris, France.
METHODS: Retrospective study of HIV-negative, HBs Ag-positive pregnant women with HBV DNA loads above 5 Log10 I.U/ml who were not given lamivudine or tenofovirDF during pregnancy between 2004 and 2011.
RESULTS: Among 11 417 pregnant women, 437 (4%) showed a positive HBs Ag. Among these women, 52 had HBV DNA loads above 5 Log10 I.U/ml: 41, 10 and 1 born in Asia, sub-Saharan Africa and Europe respectively. Among the 52 women, 40 were eligible for the analysis: no antiviral therapy during pregnancy; children over 9 months old. Twenty-eight (70%) women were assessed, corresponding to 41 childbirths. Eleven children (27%) had positive HBs Ag, 14 (34%) had positive HBc and HBs Ab, 16 (39%) had positive HBs Ab only. The risk of having positive HBs Ag, according to maternal HBV DNA loads, was 14% for HBV DNA loads less or equal to 8 Log10 I.U/ml, 42% for HBV DNA loads over 8 Log10 I.U/ml, P = 0.04, but not related to the women's origin, HBV genotype.
CONCLUSIONS: This study confirms that serovaccination does not fully protect newborns from MTC HBV transmission, when maternal HBV DNA loads exceed 5 Log10 I.U/ml, regardless of the women's origin or HBV genotype.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Asia/sub-Saharan Africa; hepatitis B virus; maternal viral load; mother-to-child transmission

Mesh:

Substances:

Year:  2014        PMID: 24698736     DOI: 10.1111/liv.12561

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

Review 1.  Elimination of Vertical Transmission of Hepatitis B in Africa: A Review of Available Tools and New Opportunities.

Authors:  Jodie Dionne-Odom; Basile Njei; Alan T N Tita
Journal:  Clin Ther       Date:  2018-07-05       Impact factor: 3.393

2.  Hepatitis B Infection and Mother-to-Child Transmission in Haiphong, Vietnam: A Cohort Study with Implications for Interventions.

Authors:  Pham Minh Khue; Nguyen Thi Thuy Linh; Vu Hai Vinh; Luu Vu Dung; Bang Nguyen Van
Journal:  Biomed Res Int       Date:  2020-08-20       Impact factor: 3.411

3.  Viral hepatitis B and C in HIV-exposed South African infants.

Authors:  Cynthia Tamandjou Tchuem; Mark Fredric Cotton; Etienne Nel; Richard Tedder; Wolfgang Preiser; Avy Violari; Raziya Bobat; Laura Hovind; Lisa Aaron; Grace Montepiedra; Charles Mitchell; Monique Ingrid Andersson
Journal:  BMC Pediatr       Date:  2020-12-24       Impact factor: 2.125

4.  Efficacy and safety of nucleos(t)ide analogues to prevent hepatitis B virus mother-to-child transmission in pregnant women with high viremia: real life practice from China.

Authors:  Qiuju Sheng; Yang Ding; Baijun Li; Chao Han; Yanwei Li; Chong Zhang; Han Bai; Jingyan Wang; Lianrong Zhao; Tingting Xia; Ziying An; Mingxiang Zhang; Xiaoguang Dou
Journal:  Int J Med Sci       Date:  2018-05-22       Impact factor: 3.738

5.  Efficacy and safety of continuous antiviral therapy from preconception to prevent perinatal transmission of hepatitis B virus.

Authors:  Xingfei Pan; Jingsi Chen; Liyang Zhou; Xueting Ou; Fang He; Yifen Liu; Shuo Zheng; Haibin Wang; Bin Cao; Zhijian Wang; Huishu Liu; Guocheng Liu; Zhenyu Huang; Guanxin Shen; Shiliang Liu; Dunjin Chen
Journal:  Sci Rep       Date:  2020-08-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.